Comparison of doxycycline–streptomycin, doxycycline–rifampin, and ofloxacin–rifampin in the treatment of brucellosis: a randomized clinical trial

• Published in: International journal of infectious diseases Vol. 16; no. 4; pp. e247 - e251
• Main Authors: Hashemi, Seyyed Hamid, Gachkar, Latif, Keramat, Fariba, Mamani, Mojgan, Hajilooi, Mehrdad, Janbakhsh, Alireza, Majzoobi, Mohammad Mehdi, Mahjub, Hossein
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.04.2012
• Subjects: Adult; Anti-Bacterial Agents - therapeutic use; Brucella melitensis - isolation & purification; Brucellosis; Brucellosis - drug therapy; Brucellosis - microbiology; Doxycycline; Doxycycline - therapeutic use; Drug Therapy, Combination; Female; Humans; Infectious Disease; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Ofloxacin - therapeutic use; Pulmonary/Respiratory; Rifampin; Rifampin - therapeutic use; Streptomycin; Streptomycin - therapeutic use; Treatment Outcome; Young Adult; Brucellosis; Streptomycin; Ofloxacin; Rifampin; Doxycycline
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2011.12.003

Summary Background Traditional regimens for the treatment of brucellosis are associated with significant relapse rates. The aim of this study was to compare the efficacy of ofloxacin plus rifampin (OFX–RIF) versus doxycycline plus streptomycin (DOX–STR) and doxycycline plus rifampin (DOX–RIF) regimens in the treatment of brucellosis. Methods Two hundred and nineteen patients with brucellosis were enrolled in a randomized clinical trial; 28 cases were withdrawn because they did not attend the follow-up. Out of 191 patients with brucellosis, 64 received OFX–RIF, 62 received DOX–RIF, and 65 patients received DOX–STR regimens. All patients were assessed during the period of therapy in the second, fourth, and sixth weeks by clinical course and were also followed up clinically and serologically for 6 months after the cessation of therapy. Results The highest clinical response (95.4%) was observed in the DOX–STR group ( p = 0.009). The results of multivariate analysis indicate that treatment with DOX–STR had the least therapeutic failures among the three groups ( p = 0.033). Adverse reactions were seen in 16.8% of patients, but there was no significant difference among the three groups ( p = 0.613). The lowest relapse rate (4.6%) was observed in the DOX–STR group ( p = 0.109). Conclusions We conclude that the DOX–STR combination should remain the first-line regimen for the treatment of brucellosis in our region; we recommend DOX–RIF and OFX–RIF combinations as the second-line regimens.